Beck Depression Inventory-Fast Screen (BDI-FS): an efficient tool for depression screening in patients with end-stage renal disease.

Depression is common in patients suffering from end-stage renal disease (ESRD). Various screening tools for depression in ESRD patients are available. This study aimed to validate the Beck Depression Inventory-Fast Screen (BDI-FS) with the Beck Depression Inventory-II (BDI-II) as depression screening tool in conventional hemodialysis (CHD) patients. One hundred sixty two CHD patients were studied with both screening questionnaires. We used the Pearson Correlation Coefficient to measure the agreement between BDI-II and BDI-FS scores from 134 patients who responded to both questionnaires. Receiver operating characteristics curve and area under the curve were constructed to determine a valid BDI-FS cutoff score to identify ESRD patients at risk for depression. BDI-II and BDI-FS scores strongly correlated (Pearson r = 0.85, p < 0.0001). At a BDI-II cutoff ≥16, receiver operating characteristics showed the best balance between sensitivity and specificity for the BDI-FS cutoff value of ≥4 with a sensitivity of 97.2% (95% confidence interval [CI]: 85.5%, 99.9%) and a specificity of 91.8% (95% CI: 84.5%, 96.4%). When applying the above cutoff scores, prevalence of depressive symptoms in all completed questionnaires was found to be 28.7% (BDI-II) and 30.1% (BDI-FS), respectively. The BDI-FS was found to be an efficient and effective tool for depression screening in ESRD patients which can be easily implemented in routine dialysis care.

A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients.

BACKGROUND: Central venous catheters (CVCs) are used for vascular access in hemodialysis patients who have no alternative access or are awaiting placement or maturation of a permanent access. The major complications of CVCs are catheter-related bloodstream infection and clotting in the catheter lumen. STUDY DESIGN: Parallel-group, randomized, multicenter clinical trial, with patients blinded to study intervention. SETTING & PARTICIPANTS: 16 free-standing dialysis facilities in Northern California belonging to a single provider. 303 adult maintenance hemodialysis patients who were using a tunneled cuffed CVC for vascular access. INTERVENTION: The treatment group received an antibiotic lock containing gentamicin 320 µg/mL in 4% sodium citrate, whereas the control group received the standard catheter lock containing heparin 1,000 U/mL. Both groups received triple-antibiotic ointment on the catheter exit site during dressing changes at each dialysis treatment. OUTCOMES: Catheter-related bloodstream infection and catheter clotting. MEASUREMENTS: Catheter-related bloodstream infection was defined as the occurrence of symptoms consistent with bacteremia together with positive blood culture results in the absence of another obvious source of infection. Catheter clotting was measured as the rate of thrombolytic agent use required to maintain adequate blood flow. A single patient could contribute more than one infection or clotting episode. RESULTS: The rate of catheter-related bloodstream infection was 0.91 episodes/1,000 catheter-days in the control group and 0.28 episodes/1,000 catheter-days in the treatment group (P = 0.003). The time to the first episode of bacteremia was significantly delayed (P = 0.005). The rates of tissue plasminogen activator use were similar in the treatment and control groups: 2.36 versus 3.42 events/1,000 catheter-days, respectively (P = 0.2). LIMITATIONS: The requirement for dialysis facility staff to prepare the treatment intervention prevented a completely blinded study. CONCLUSION: Gentamicin 320 µg/mL in 4% sodium citrate used as a routine catheter lock in CVCs in patients on maintenance hemodialysis therapy markedly decreases the incidence of catheter-related bloodstream infection and is as effective as heparin 1,000 U/mL in preventing catheter clotting.

Dialysis overnight: in-center nocturnal hemodialysis programs showing growth.

Toxin and fluid removal are the main goals of dialysis therapy for patients with end-stage renal disease. Recent data indicate that the BUN-centered delivery of dialysis therapy with high efficiency, conventional, thrice-weekly hemodialysis therapy may fall short on the likewise critically important fluid control. Extended hour, in-center nocturnal HD (INHD) emerges as one of the alternative therapies for patients whose clinical needs are not met with conventional HD or who are seeking a dialysis therapy less interfering with daytime activities. We report the logistic requirements for a nocturnal program evaluated in a pilot at a midsize non-profit dialysis provider. In-center nocturnal hemodialysis provides longer dialysis sessions similar to the thrice-weekly 8-10 hour dialysis treatments originally prescribed in the early days of dialysis. INHD allows for a more flexible lifestyle-oriented dialysis schedule and enables patients to maintain routine daytime activities. It also offers an alternative schedule for patients who require extended-hour dialysis for various medical reasons.

Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study.

BACKGROUND: Patients on in-center nocturnal hemodialysis therapy typically experience higher interdialytic weight gain (IDWG) than patients on conventional hemodialysis therapy. We determined the safety and effects of decreasing dialysate sodium concentration on IDWG and blood pressure in patients on thrice-weekly in-center nocturnal hemodialysis therapy. STUDY DESIGN: Quality improvement, pre-post intervention. SETTINGS & PARTICIPANTS: 15 participants in a single facility. QUALITY IMPROVEMENT PLAN: Participants underwent three 12-week treatment phases, each with different dialysate sodium concentrations, as follows: phase A, 140 mEq/L; phase B, 136 or 134 mEq/L; and phase A(+), 140 mEq/L. Participants were blinded to the exact timing of the intervention. OUTCOMES: IDWG, IDWG/dry weight (IDWG%), and blood pressure. MEASUREMENTS: Outcome data were obtained during the last 2 weeks of each phase and compared with mixed models. The fraction of sessions with adverse events (eg, cramping and hypotension) also was reported. RESULTS: IDWG, IDWG%, and predialysis systolic blood pressure decreased significantly by 0.6 ± 0.6 kg, 0.6% ± 0.8%, and 8.3 ± 14.9 mm Hg, respectively, in phase B compared with phase A (P < 0.05 for all comparisons). No differences in predialysis diastolic and mean arterial or postdialysis blood pressures were found (P > 0.05 for all comparisons). The proportion of treatments with intradialytic hypotension was low and similar in each phase (P = 0.9). In phase B compared with phase A, predialysis plasma sodium concentration was unchanged (P > 0.05), whereas postdialysis plasma sodium concentration decreased by 3.7 ± 1.9 mEq/L (P < 0.05). LIMITATIONS: Modest sample size. CONCLUSION: Decreasing dialysate sodium concentrations in patients undergoing thrice-weekly in-center nocturnal hemodialysis resulted in a clinical and statistically significant decrease in IDWG, IDWG%, postdialysis plasma sodium concentration, and predialysis systolic blood pressure without increasing adverse events. Prolonged exposure to higher than required dialysate sodium concentrations may drive IDWG and counteract some of the purported benefits of "go-slow" (longer session length) hemodialysis.

Patient-nurse partnerships.

Healthcare reform is moving toward a patient-centered model of care. Effective patient-nurse partnerships are essential in a patient-centered model of care, with the patient assuming a more active empowered role. While many play a vital role in the success of the partnership, including the patient, family, nurse, and healthcare team, this article reviews the patient, the nurse, and the partnership incorporating current evidence and case studies. The intention of this article is not to present a specific model of a successful partnership, but to provoke thought and provide available resources.

Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach?

BACKGROUND: A higher sodium gradient (dialysate sodium minus pre-dialysis plasma sodium) during hemodialysis (HD) has been associated with sodium loading; however, its role is not well studied. We hypothesized that a sodium dialysate prescription resulting in a higher sodium gradient is associated with increases in interdialytic weight gain (IDWG), blood pressure (BP) and thirst. METHODS: We conducted a cross-sectional study on 1084 clinically stable patients on HD. A descriptive analysis of the sodium prescription was performed and clinical associations with sodium gradient were analyzed. RESULTS: The dialysate sodium prescription varied widely across dialysis facilities, ranging from 136 to 149 mEq/L, with a median of 140 mEq/L. The mean pre-HD plasma sodium was 136.7 ± 2.9 mEq/L, resulting in the majority of subjects (n = 904, 83%) being dialyzed against a positive sodium gradient, while the mean sodium gradient was 4.6 ± 4.4 mEq/L. After HD, the plasma sodium increased in nearly all patients (91%), reaching a mean post-HD plasma sodium of 141.3 ± 2.5 mEq/L. We found a direct correlation between IDWG and sodium gradient (r = 0.21, P < 0.0001). After adjustment for confounders and clustering by facilities, the sodium gradient was independently associated with IDWG (70 g/mEq/L, P < 0.0001). There were no significant associations among sodium gradient and BP, whether measured as pre-HD systolic (r = -0.02), diastolic (r = -0.06) or mean arterial pressure (r = -0.04). Post-HD thirst was directly correlated with sodium gradient (r = 0.11, P = 0.02). CONCLUSION: Sodium gradient is associated with statistically significant and clinically meaningful differences in IDWG in stable patients on HD.

Perceptions about renal replacement therapy among nephrology professionals.

Usage of renal replacement modalities available for the treatment of end stage renal disease varies widely between countries, indicating that non-medical factors contribute to the choice of therapy. In the United States, 93% of the patients are treated with in-center hemodialysis (HD), about 7% undergo peritoneal dialysis (PD) and less than 1% are on home HD. In comparison, a Northern California-based nonprofit dialysis provider with home dialysis centers throughout the United States has achieved a home therapy penetration of 22%, the highest proportion of home therapies among U.S. dialysis providers. To better understand the perceptions about the various modality choices among caretakers (nephrologists and nurses) in this organization a short questionnaire was used. We examined the hypothetical setting of the caretakers being in the patient role. More than 90% of the nephrology professionals chose a home therapy as initial treatment option with close to equal distribution between PD and home HD. This pattern persisted for maintenance therapy with home HD being the preferred modality. Nephrologists' and nurses' perception of who makes modality decisions varied profoundly.

Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.

Erythropoiesis stimulating agents (ESAs) have revolutionized the management of anemia of chronic kidney disease (CKD). Peginesatide is an investigational pegylated, peptide-based, once-monthly ESA for increasing and maintaining hemoglobin (Hb). In phase 2 studies, peginesatide increases and maintains target Hb levels in patients with CKD, both those on hemodialysis and those not on hemodialysis; phase 3 trials have recently been completed. This article discusses unmet needs in the management of anemia of CKD, presents peginesatide attributes, reviews the results of select peginesatide clinical studies, and discusses the potential value of peginesatide as an alternative anemia management option.

Clinical research: making it work in the outpatient dialysis facility.

Performing clinical research in the outpatient dialysis facility can be very challenging. Research protocols define time-specific and detailed procedures to be performed. In dialysis units where staff members are responsible for the delivery of life-sustaining therapy to an aging end stage renal disease patient population with multiple co-morbidities, these requirements can easily be considered too burdensome to be implemented successfully. In the authors'facility, clinical research has been successfully implemented with a close team approach supported by a dedicated research group and unit staff

Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.

Use of erythropoiesis-stimulating agents (ESAs) presents a significant time and cost burden in the management of anemia of chronic kidney disease (CKD). We conducted a prospective, observational, activity-based costing study to estimate the health care personnel time and resulting direct medical costs associated with administering epoetin 3 times weekly to patients with end-stage renal disease on dialysis. The study was conducted at 5 US hemodialysis centers. The personnel time and costs were derived from time and motion observations. Predicted time and cost savings were modeled for switching patients to once-monthly ESA therapy. Patients also completed a survey questionnaire to assess their level of CKD knowledge and information needs. Total per-patient-per-year (PPPY) time expended on anemia management with epoetin averaged 608 minutes (range 512-915 minutes), with an average PPPY cost of $548 (range $342-$651). Use of a once-monthly ESA, compared with epoetin, could decrease average PPPY time expenditure by 79% (127 minutes [range 96-173 minutes]) and reduce PPPY costs by 81% ($104 [range $79-$136]). The patient questionnaire reported insufficient education on CKD. Use of a once-monthly ESA to correct anemia in dialysis patients may provide substantial time, resource, and cost savings compared with current treatment practices.

Buttonhole cannulation--an unexpected outcome.

The buttonhole method of needle insertion has been reported to be a safe and effective means of cannulation. In general, infections in patients with arteriovenous fistula access are considered to be infrequent compared to other types of accesses. Although minimal data exist regarding infection rates with buttonhole cannulation, these authors' data indicate that the infection rate with buttonhole cannulation may be underestimated.

A comparison of dual dialyzers in parallel and series to improve urea clearance in large hemodialysis patients.

BACKGROUND: Dialysis adequacy targets frequently are difficult to achieve in large hemodialysis patients. Dual dialyzers can be used to improve clearance. It is unknown whether series or parallel configurations are superior. METHODS: Eighteen large hemodialysis patients (mean weight, 92.4 kg) were enrolled in a randomized, crossover trial to directly compare dual dialyzers in parallel and series configurations. Treatment times, blood flow rates, and dialysate flow rates were kept constant. RESULTS: Compared with a single dialyzer, parallel dual dialyzers increased the single-pool Kt/V (spKt/V) from 1.25 +/- 0.22 to 1.43 +/- 0.29 (P < 0.003). Series dual dialyzers improved urea clearance measured by spKt/V (spKt/V(urea)) to 1.46 +/- 0.26 (P < 0.0003 compared with a single dialyzer). Kt/V and urea reduction ratio of dual dialyzers in parallel were not significantly different from those of dual dialyzers in series. Half the subjects failed to meet the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative recommended adequacy target for spKt/V(urea) of 1.2 or less using a single dialyzer. With the use of dual dialyzers, 83% of subjects achieved this adequacy target. Serum levels of a middle molecule, beta2-microglobulin, were reduced 34% after 2 months of dual-dialyzer therapy. Cost analysis estimates annual net savings of 1,260 dollars with dual-dialyzer therapy, primarily from projected savings in inpatient expenses. CONCLUSION: In large hemodialysis patients, our study shows that dual dialyzers in parallel and series are equally effective at improving urea clearance without prolonging dialysis treatment times.